SGHT NASDAQ
Credit Risk of going bust: higher than 64% of companies Debt: 7.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.14 (down 98%), Sight Sciences, Inc. would be worth roughly what it owes.
Total debt $42.0M against a stock market value of $497.4M.
Distance to default 3.93 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $25.5M (short-term plus half of long-term), stock volatility 75.0%; Altman Z 1.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Menlo Park, CA 94025
US
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Taylor Brenton | S-Sale | 2,988 | $8.85 | 2026-10-02 |
| Bauerlein Alison | S-Sale | 25,260 | $8.85 | 2026-10-02 |
| Rodberg James | S-Sale | 7,208 | $8.85 | 2026-10-02 |
| Badawi David | S-Sale | 7,797 | $9.05 | 2026-10-01 |
| Badawi Paul | S-Sale | 29,653 | $9.05 | 2026-10-01 |